Renal denervation was one of the hot topics at EuroPCR 2018 — what has changed to bring it back to the forefront of hypertension therapy? Let investigators Felix Mahfoud, Andrew Sharp, and David Kandzari guide you through the intricacies of SPYRAL-ON, which assessed the intervention in patients with moderate hypertension uncontrolled by drug therapy. A. Sharp explains how the design differed from studies that went before, and included rigorous and extensive controlling for variables that affected previous trials. D. Kandzari talks about how the trial “raises the concept of an ‘always on’ effect of renal denervation”, and what it teaches us about adherence to medical therapy. Together, the investigators discuss efficacy and safety issues, and look at future trials that, D. Kandzari hopes, will lead “ideally to regulatory approval, but also inform clinical practice”. F. Mahfoud promises “exciting times for renal denervation”, with “much more to come”.

The content of this video is offered by Medtronic and was filmed at EuroPCR 2018. See more videos here: [ Ссылка ]

свернуть